Texas Biotechnology argatroban
This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryAnticoagulant will be launched in the third quarter, marketing partner SmithKline Beecham says. Argatroban was approved June 30 for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia. SmithKline has not yet decided on a brand name for the product, which was approved as Acova. FDA rejected the initial tradename, Novastan, because of its similarity to Immunex's Novantrone
You may also be interested in...
New research links the use of stents and balloons coated with the drug paclitaxel to an increased risk of lower-leg amputation shortly following surgery. The study was conducted by Greek researcher Konstantinos Katsanos, who previously found an increased mortality risk in paclitaxel-treated patients.
Monia told Scrip at the J.P. Morgan Healthcare Conference that the company will be more selective about partnerships going forward and build commercial capabilities to market Ionis-owned drugs.
Smith & Nephew has acquired Tusker Medical for an undisclosed price. The acquisition comes just months after Tusker’s Tula system was approved by the FDA as a breakthrough device.